Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Cautious on elevated broad-market valuations and rising rate pressures, leaning into high-quality healthcare and industrials while initiating longs in $GNRC, $RIG, and $ESAB.
Full Quick Take
Cautious on elevated broad-market valuations and rising rate pressures, leaning into high-quality healthcare and industrials while initiating longs in $GNRC, $RIG, and $ESAB.
Holding substantial cash reserves while redeploying harvested capital from mature infrastructure into deeply discounted residential real estate and depressed payment processors amid speculative market bifurcation.
Full Quick Take
Holding substantial cash reserves while redeploying harvested capital from mature infrastructure into deeply discounted residential real estate and depressed payment processors amid speculative market bifurcation.
Accelerating pharmaceutical patent expiries and pipeline failures are driving historic acquisition demand, anchoring biotechnology fundamentals even as benchmark Treasury yields surpass five percent.
Full Quick Take
Accelerating pharmaceutical patent expiries and pipeline failures are driving historic acquisition demand, anchoring biotechnology fundamentals even as benchmark Treasury yields surpass five percent.
McElvaine Value Fund emphasizes balance sheet resilience over thematic investing, holding concentrated positions in owner-managed businesses with net cash or minimal debt.
Full Quick Take
McElvaine Value Fund emphasizes balance sheet resilience over thematic investing, holding concentrated positions in owner-managed businesses with net cash or minimal debt.
Capitalizing on improved biotech sentiment driven by FDA leadership changes, strong M&A including AbbVie's $10.9 billion acquisition of portfolio company Apogee, and positive late-stage oncology data at ASCO.
Full Quick Take
Capitalizing on improved biotech sentiment driven by FDA leadership changes, strong M&A including AbbVie's $10.9 billion acquisition of portfolio company Apogee, and positive late-stage oncology data at ASCO.
Lagging the benchmark's 10.82% as AI-driven concentration dominated markets. Financials and health care detracted on capital markets weakness and cost inflation concerns.
Full Quick Take
Lagging the benchmark's 10.82% as AI-driven concentration dominated markets. Financials and health care detracted on capital markets weakness and cost inflation concerns.
Baillie Gifford's International Growth strategy exploits market short-termism to build a diversified portfolio of high-quality growth companies positioned for AI transformation and structural change.
Full Quick Take
Baillie Gifford's International Growth strategy exploits market short-termism to build a diversified portfolio of high-quality growth companies positioned for AI transformation and structural change.
Driven by AI semiconductor infrastructure (SK hynix, Samsung) and healthcare innovation (Lantheus M&A, CVS GLP-1). The manager rotated from richly valued names into Adobe, Fujifilm, UniCredit, and Booking Holdings, viewing market concentration as creating value dislocations.
Full Quick Take
Driven by AI semiconductor infrastructure (SK hynix, Samsung) and healthcare innovation (Lantheus M&A, CVS GLP-1). The manager rotated from richly valued names into Adobe, Fujifilm, UniCredit, and Booking Holdings, viewing market concentration as creating value dislocations.
Utilities Plus outperformed in Q2 2026 despite rate headwinds, benefiting from small/mid-cap regulated utility strength and data center power demand. The portfolio added to Xcel Energy on valuation.
Full Quick Take
Utilities Plus outperformed in Q2 2026 despite rate headwinds, benefiting from small/mid-cap regulated utility strength and data center power demand. The portfolio added to Xcel Energy on valuation.
Capitalizing on deeply discounted small-cap healthcare opportunities. The concentrated portfolio benefited from M&A activity, strong product launches at Liquidia and Electromed, and a 106% gain on Avanos acquisition.
Full Quick Take
Capitalizing on deeply discounted small-cap healthcare opportunities. The concentrated portfolio benefited from M&A activity, strong product launches at Liquidia and Electromed, and a 106% gain on Avanos acquisition.
Brandes International Equity underperformed in Q2 2026 as AI-driven technology concentration dominated markets. The manager trimmed semiconductor winners and maintains conviction in mission-critical enterprise software despite near-term pressure.
Full Quick Take
Brandes International Equity underperformed in Q2 2026 as AI-driven technology concentration dominated markets. The manager trimmed semiconductor winners and maintains conviction in mission-critical enterprise software despite near-term pressure.
The concentrated portfolio now holds significant cash following exits, with new position AnaptysBio offering 50-80% upside as GSK litigation approaches trial in July.
Full Quick Take
The concentrated portfolio now holds significant cash following exits, with new position AnaptysBio offering 50-80% upside as GSK litigation approaches trial in July.
Underperforming on AI enthusiasm but maintaining long-term outperformance. Samsung rallied on AI-driven memory demand while BMW fell on China weakness.
Full Quick Take
Underperforming on AI enthusiasm but maintaining long-term outperformance. Samsung rallied on AI-driven memory demand while BMW fell on China weakness.
Westfield trimmed AI exposure after semiconductors hit technical extremes, rotating into Healthcare, Industrials, and Financials. Healthcare offers compelling value with earnings inflection and $1.4 trillion pharma M&A firepower.
Full Quick Take
Westfield trimmed AI exposure after semiconductors hit technical extremes, rotating into Healthcare, Industrials, and Financials. Healthcare offers compelling value with earnings inflection and $1.4 trillion pharma M&A firepower.
Matching the market despite avoiding AI beneficiaries. The manager views AI infrastructure spending as unsustainable, with the six largest spenders approaching $1trn annually requiring unrealistic returns.
Full Quick Take
Matching the market despite avoiding AI beneficiaries. The manager views AI infrastructure spending as unsustainable, with the six largest spenders approaching $1trn annually requiring unrealistic returns.
ARK Invest remains intensely bullish on disruptive innovation platforms, projecting that accelerating productivity from converging frontier technologies will suppress inflation and drive outsized growth.
Full Quick Take
ARK Invest remains intensely bullish on disruptive innovation platforms, projecting that accelerating productivity from converging frontier technologies will suppress inflation and drive outsized growth.
Concentrated global growth fund underperformed significantly in Q1 2026 despite strong individual company fundamentals. Manager maintains high conviction in technology leaders like Arm Holdings benefiting from AI adoption and Tesla's EV/autonomy evolution.
Full Quick Take
Concentrated global growth fund underperformed significantly in Q1 2026 despite strong individual company fundamentals. Manager maintains high conviction in technology leaders like Arm Holdings benefiting from AI adoption and Tesla's EV/autonomy evolution.
Arquitos targets liquidating biotechs trading below cash value and patent-driven pharmaceutical plays. Manager most bullish ever on Liquidia Corporation, expecting $70-140 per share regardless of pending patent decision.
Full Quick Take
Arquitos targets liquidating biotechs trading below cash value and patent-driven pharmaceutical plays. Manager most bullish ever on Liquidia Corporation, expecting $70-140 per share regardless of pending patent decision.
Concentrated small-cap healthcare value fund delivered strong long-term returns despite Q1 underperformance. Avanos Medical takeout at 72% premium exemplifies M&A-driven value realization strategy.
Full Quick Take
Concentrated small-cap healthcare value fund delivered strong long-term returns despite Q1 underperformance. Avanos Medical takeout at 72% premium exemplifies M&A-driven value realization strategy.
Capital markets are reopening with follow-on activity tripling year-over-year. The concentrated biotech portfolio focuses on transformative life sciences assets with major oncology catalysts expected at upcoming medical conferences.
Full Quick Take
Capital markets are reopening with follow-on activity tripling year-over-year. The concentrated biotech portfolio focuses on transformative life sciences assets with major oncology catalysts expected at upcoming medical conferences.
Fund outperformed with 2.4% gain versus S&P 500's 4.3% decline in volatile Q1 2026. Iran conflict drove energy sector strength while AI disruption pressured software holdings.
Full Quick Take
Fund outperformed with 2.4% gain versus S&P 500's 4.3% decline in volatile Q1 2026. Iran conflict drove energy sector strength while AI disruption pressured software holdings.
Arbitrage strategy benefited from biotech acquisitions and energy sector strength during Iran conflict. Fund positioned in pending deals including AES Corp and Tri Pointe Homes with continued M&A momentum expected.
Full Quick Take
Arbitrage strategy benefited from biotech acquisitions and energy sector strength during Iran conflict. Fund positioned in pending deals including AES Corp and Tri Pointe Homes with continued M&A momentum expected.
WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defending software, defense, and vision positions amidst short-term volatility.
Full Quick Take
WS Amati Global Innovation Fund capitalized on AI infrastructure and biotech gains in Q4 2025, actively purchasing underpriced growth names like Fabrinet and H.U. Group while defending software, defense, and vision positions amidst short-term volatility.
The fund underperformed in October despite strong pharmaceutical holdings GSK and AstraZeneca raising guidance. Technology holdings faced headwinds with leadership changes and margin pressure.
Full Quick Take
The fund underperformed in October despite strong pharmaceutical holdings GSK and AstraZeneca raising guidance. Technology holdings faced headwinds with leadership changes and margin pressure.
Strong Q3 performance driven by healthcare winners UCB and Sandoz, plus semiconductor recovery positioning. Defense and AI infrastructure themes supported by quality holdings.
Full Quick Take
Strong Q3 performance driven by healthcare winners UCB and Sandoz, plus semiconductor recovery positioning. Defense and AI infrastructure themes supported by quality holdings.
Small-cap growth manager outperformed benchmarks with +18-25% Q3 returns, focusing on healthcare companies with new products and large market opportunities.
Full Quick Take
Small-cap growth manager outperformed benchmarks with +18-25% Q3 returns, focusing on healthcare companies with new products and large market opportunities.
The portfolio underperformed in Q3 2025 as the market favored high-beta momentum stocks and commodity miners. Harding Loevner remains anchored in its long-term quality-compounder strategy, adding to resilient IT services and health care equipment holdings on weakness.
Full Quick Take
The portfolio underperformed in Q3 2025 as the market favored high-beta momentum stocks and commodity miners. Harding Loevner remains anchored in its long-term quality-compounder strategy, adding to resilient IT services and health care equipment holdings on weakness.
VELA International outperformed in Q3 with 7.43% returns while maintaining 9.5% defensive cash position. Added healthcare and consumer names at attractive valuations amid tariff uncertainty.
Full Quick Take
VELA International outperformed in Q3 with 7.43% returns while maintaining 9.5% defensive cash position. Added healthcare and consumer names at attractive valuations amid tariff uncertainty.
Healthcare holdings faced sector headwinds from administration policy uncertainty. Portfolio trades at widest discount to intrinsic value since mid-2022.
Full Quick Take
Healthcare holdings faced sector headwinds from administration policy uncertainty. Portfolio trades at widest discount to intrinsic value since mid-2022.
Halvio Capital focuses on deep value opportunities, particularly in Japan where companies trade at significant discounts to book value with strong balance sheets.
Full Quick Take
Halvio Capital focuses on deep value opportunities, particularly in Japan where companies trade at significant discounts to book value with strong balance sheets.
The concentrated portfolio emphasizes profitable businesses trading below intrinsic value with substantial downside protection through excess cash or undervalued assets, particularly benefiting from ongoing Japanese corporate reforms and liquidation scenarios.
Full Quick Take
The concentrated portfolio emphasizes profitable businesses trading below intrinsic value with substantial downside protection through excess cash or undervalued assets, particularly benefiting from ongoing Japanese corporate reforms and liquidation scenarios.
Halvio Capital focuses on deep value opportunities, particularly in Japan where corporate reforms are unlocking value in cash-rich companies trading below book value.
Full Quick Take
Halvio Capital focuses on deep value opportunities, particularly in Japan where corporate reforms are unlocking value in cash-rich companies trading below book value.
Global growth fund underperformed in Q1 2025 with -3.35% returns versus -1.32% benchmark. Strong performance from MercadoLibre, Alibaba, and Novartis offset weakness in Tesla, Alphabet, and Amazon.
Full Quick Take
Global growth fund underperformed in Q1 2025 with -3.35% returns versus -1.32% benchmark. Strong performance from MercadoLibre, Alibaba, and Novartis offset weakness in Tesla, Alphabet, and Amazon.
Strong Q1 performance driven by European small-cap exposure, outperforming benchmark by 484 basis points. Portfolio activity included strategic additions in luxury fashion, pharmaceutical packaging, and cloud services while exiting positions at fair value.
Full Quick Take
Strong Q1 performance driven by European small-cap exposure, outperforming benchmark by 484 basis points. Portfolio activity included strategic additions in luxury fashion, pharmaceutical packaging, and cloud services while exiting positions at fair value.
RTW Bio outperformed biotech indices despite -6.4% Q1 return as sector valuations hit new lows. Portfolio concentrated in high unmet need rare diseases and oncology with strong FDA support.
Full Quick Take
RTW Bio outperformed biotech indices despite -6.4% Q1 return as sector valuations hit new lows. Portfolio concentrated in high unmet need rare diseases and oncology with strong FDA support.